Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Kirin-do: Double-digit Increases in Sales, Profits
April 16, 2001
- Criteria for Disclosure, Non-disclosure Published
April 16, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 16, 2001
- Hitachi, Myriad, Oracle, Friedli to Tie Up in Proteomics
April 16, 2001
- JPA Leader Comments on New Deregulation Promotion Plan
April 16, 2001
- Sankyo to Be Aggressive in Genomic Drug Discovery: Dr Hiraoka
April 16, 2001
- Toyama to Exclusively Market YP-14 Jointly Developed with Taiho
April 16, 2001
- Review of NHI Price System Included in New Deregulation Plan
April 16, 2001
- Daiichi, Medtronic Codevelop Intrathecal Baclofen Therapy
April 16, 2001
- Novartis to Double Sales in 5 Years in Transplantation, Immunology, Cancer
April 16, 2001
- REGULATORY NEWS IN BRIEF -1-
April 16, 2001
- Kirin Brewery to Survive by Focusing on Cancer, Nephrology, Allergy/Immunology
April 16, 2001
- The Cues in Pharma Communication (2)
April 16, 2001
- Quintiles to Double Its Sales in Japan in FY2001
April 16, 2001
- REGULATORY NEWS IN BRIEF -2-
April 16, 2001
- Immediate PMS of Mobic Undertaken by Nippon Boehringer Ingelheim, Daiichi
April 16, 2001
- Bungyo Rate Exceeds 40%for Two Consecutive Months
April 16, 2001
- Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
April 16, 2001
- Reform of Medical Education Proposed to Promote Patient-centered Healthcare
April 16, 2001
- BUSINESS NEWS IN BRIEF -2-
April 16, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…